Literature DB >> 10506659

Engineering parvovirus-like particles for the induction of B-cell, CD4(+) and CTL responses.

P Rueda1, J L Martínez-Torrecuadrada, J Sarraseca, C Sedlik, M del Barrio, A Hurtado, C Leclerc, J I Casal.   

Abstract

An antigen delivery system based on hybrid recombinant parvovirus-like particles (VLPs) formed by the self-assembly of the capsid VP2 protein of porcine (PPV) or canine parvovirus (CPV) expressed in insect cells with the baculovirus system has been developed. PPV:VLPs containing a CD8(+) epitope from the LCMV nucleoprotein evoked a potent CTL response and were able to protect mice against a lethal infection with the virus. Also, PPV:VLPs containing the C3:T epitope from poliovirus elicited a CD4(+)3 log(10) units) against poliovirus. The possibility of combining different types of epitopes in different positions of a single particle to stimulate different branches of the immune system paves the way to the production of more potent vaccines in a simple and cheap way.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10506659     DOI: 10.1016/s0264-410x(99)00202-9

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Influence of minor displacements in loops of the porcine parvovirus VP2 capsid on virus-like particles assembly and the induction of antibody responses.

Authors:  Qunxing Pan; Kongwang He; Yongshan Wang; Xiaoli Wang; Wei Ouyang
Journal:  Virus Genes       Date:  2013-02-21       Impact factor: 2.332

2.  A highly optimized DNA vaccine confers complete protective immunity against high-dose lethal lymphocytic choriomeningitis virus challenge.

Authors:  Devon J Shedlock; Kendra T Talbott; Christina Cress; Bernadette Ferraro; Steven Tuyishme; Karthik Mallilankaraman; Neil J Cisper; Matthew P Morrow; Stephan J Wu; Omkar U Kawalekar; Amir S Khan; Niranjan Y Sardesai; Karuppiah Muthumani; Hao Shen; David B Weiner
Journal:  Vaccine       Date:  2011-01-14       Impact factor: 3.641

3.  Immunogenicity and safety of virus-like particle of the porcine encephalomyocarditis virus in pig.

Authors:  Hye-Young Jeoung; Won-Ha Lee; WooSeog Jeong; Bo-Hye Shin; Hwan-Won Choi; Hee Soo Lee; Dong-Jun An
Journal:  Virol J       Date:  2011-04-15       Impact factor: 4.099

4.  Memory immune responses against pandemic (H1N1) 2009 influenza virus induced by a whole particle vaccine in cynomolgus monkeys carrying Mafa-A1*052:02.

Authors:  Masahiko Arikata; Yasushi Itoh; Masatoshi Okamatsu; Toshinaga Maeda; Takashi Shiina; Keiko Tanaka; Shingo Suzuki; Misako Nakayama; Yoshihiro Sakoda; Hirohito Ishigaki; Ayato Takada; Hideaki Ishida; Kosuke Soda; Van Loi Pham; Hideaki Tsuchiya; Shinichiro Nakamura; Ryuzo Torii; Takeshi Shimizu; Hidetoshi Inoko; Iwao Ohkubo; Hiroshi Kida; Kazumasa Ogasawara
Journal:  PLoS One       Date:  2012-05-18       Impact factor: 3.240

5.  Truncated forms of viral VP2 proteins fused to EGFP assemble into fluorescent parvovirus-like particles.

Authors:  Leona Gilbert; Jouni Toivola; Outi Välilehto; Taija Saloniemi; Claire Cunningham; Daniel White; Anna R Mäkelä; Eila Korhonen; Matti Vuento; Christian Oker-Blom
Journal:  J Nanobiotechnology       Date:  2006-12-08       Impact factor: 10.435

Review 6.  Virus-like particles for vaccination against cancer.

Authors:  Mona O Mohsen; Daniel E Speiser; Alexander Knuth; Martin F Bachmann
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-08-27

7.  Investigation of Kluyveromyces marxianus as a novel host for large-scale production of porcine parvovirus virus-like particles.

Authors:  Deqiang Yang; Lei Chen; Jinkun Duan; Yao Yu; Jungang Zhou; Hong Lu
Journal:  Microb Cell Fact       Date:  2021-01-25       Impact factor: 5.328

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.